As the nation debates continuing coronavirus stimulus, AEI offers an eye-opening analysis:  Unemployment…
CFIF on Twitter CFIF on YouTube
Images of the Day: Unemployment Claims Plummeted Faster After $600 Checks Expired

As the nation debates continuing coronavirus stimulus, AEI offers an eye-opening analysis:  Unemployment claims plummeted and the employment picture improved much faster after those $600 checks expired, reestablishing that while we always want to help those who cannot help themselves, government payouts can sometimes reduce incentives and ability to return to the workforce.  And this doesn't even reflect remarkably positive employment reports released by the government since the end dates:

 

[caption id="" align="alignleft" width="562"] Continuing Unemployment Claims Dropped[/caption]

 

 

 

 

[caption id="" align="alignleft" width="563"] Initial Unemployment Claims Dropped[/caption]…[more]

November 12, 2020 • 11:57 AM

Liberty Update

CFIFs latest news, commentary and alerts delivered to your inbox.
Jester's CourtroomLegal tales stranger than stranger than fiction: Ridiculous and sometimes funny lawsuits plaguing our courts.
Misguided “Buy American” Mandates Threaten New U.S. Drug Innovation Print
By Timothy H. Lee
Thursday, June 18 2020
A 'Buy American' mandate is simply unfeasible, and its costs would far exceed any hypothetical benefits.

Well, that didn’t take long. 

Just three months into the coronavirus lockdown, multiple vaccines are already set to enter final testing on an accelerated schedule next month, well ahead of the autumn timetable originally forecast. 

Moderna Inc.’s vaccine will be tested first, followed by Johnson & Johnson’s in the latter half of July, well ahead of its initial September expectation.  Pfizer Inc. could also initiate final-stage testing in July, according to sources. 

It’s little surprise that American pharmaceutical innovators, which account for an incredible two-thirds of all new drugs introduced worldwide, would lead the way in this manner.  Few people, however, expected this degree of success so quickly. 

It all reconfirms the way in which America’s system of strong intellectual property protections and free market incentives continue to sustain the world’s leading pharmaceutical industry and the lifesaving drugs we continue to produce. 

A misguided new “Buy American” pharmaceutical proposal under consideration by the Trump Administration and certain Members of Congress, however, threatens to upend that leadership position. 

Under the contemplated legislation and executive order, all components of pharmaceuticals purchased with federal funds must originate in America.  The problem is that such a rule would disrupt longstanding pharmaceutical supply chains, instantly trigger a chain reaction of retaliation from friendly U.S. trading partners and suddenly jeopardize American consumers’ access to necessary medicines, as detailed by a coalition of conservative organizations led by Americans for Tax Reform (ATR) and joined by CFIF: 

The proposal risks upending the complex medical supply chain.  This supply chain incorporates numerous inputs from across the world, including raw materials, active pharmaceutical ingredients (APIs), and high-precision analytical tools.  These supply chains frequently contend with a number of challenges, including transportation and logistical obstacles, ensuring supply and demand are met, and alleviate stress caused to the chain due to region-specific disruptions in manufacturing shortages. 

The ability of private industry to utilize a diverse global supplier base is essential to creating a healthy competitive advantage and mitigating risk.  Forcibly localizing this supply chain would be a substantial undertaking, which would require finding new sourcing in the U.S.  If there is no existing alternative, it would be a long process to set up an alternative.  Rather than restoring U.S. jobs, the proposal would likely lead to higher prices and reduced access. 

A “Buy American” mandate is simply unfeasible, and its costs would far exceed any hypothetical benefits. 

Some may respond that a “Buy American” rule is nevertheless necessary to counteract the dominant role played by China, whose malfeasance has been exposed to the world throughout the coronavirus pandemic. 

The problem with that response is that China actually plays a decidedly minor role in American pharmaceutical manufacturing.  

According to the Food and Drug Administration’s (FDA’s) own Janet Woodcock, M.D., for instance, 28% of domestic pharmaceutical ingredients are already produced here in the U.S., with the European Union accounting for 26%, followed by India with 18%, and China accounting for only 13%.  In terms of overall drug sourcing of all types, China trails such longstanding U.S. allies as Ireland, Switzerland, Germany, Italy, India, Belgium, Denmark, Canada, the United Kingdom, Japan, the Netherlands, Singapore, France, Israel, South Korea and Austria. 

Accordingly, any “stick it to China” rationale rests upon faulty assumptions. 

Fortunately, better alternatives to the contemplated “Buy American” regulation exist to promote future domestic manufacturing and sourcing. 

In the U.S. Senate side, Marsha Blackburn (R – Tennessee) has introduced the SAM-C Act, and in the House of Representatives, Congressman Chip Roy (R – Texas) has introduced the BEAT China Act.  Both bills would offer tax credits to incentivize manufacturers to return to U.S. shores, while avoiding catastrophic disruption of current supply chains in this moment of existing urgency.  Other proposals include lowering existing tariffs with China’s rival nations, which would simultaneously encourage new allies to the U.S., boost international pressure on China and open alternative venues to sourcing currently in China. 

Amid the urgency created by the coronavirus pandemic, we simply cannot needlessly disrupt U.S. pharmaceutical innovators’ existing global supply chains with such illusory potential benefit.  Instead, we must maintain the attributes that continue to place America atop the world in terms of lifesaving drug creation:  market incentives and strong patent rights. 

That system is already paying dividends in fighting coronavirus, and we can’t allow well-meaning but counterproductive “Buy American” mandates to upend that. 

Question of the Week   
Thanksgiving was established as an annual event by which of the following presidents?
More Questions
Quote of the Day   
 
"Georgia is emerging as an early proving ground for the 2024 presidential race, with a handful of potential Republican hopefuls flocking to the state to test their political coattails in its two Senate runoffs.Sen. Rick Scott (R-Fla.), who just landed the chairmanship at the National Republican Senatorial Committee, is among the prospective 2024 contenders who have visited Georgia in recent weeks.…[more]
 
 
—Max Greenwood, The Hill
— Max Greenwood, The Hill
 
Liberty Poll   

Are you spending more or less on Black Friday and Cyber Monday than you did last year?